Work on drug pricing legislation is underway in Congress, with two House committees holding hearings on the topic in May. The most likely changes are PBM regulation, lowering out-of-pocket costs for Medicare Part D beneficiaries, allowing HHS to negotiate drug prices for Medicare patients, and limiting year-to-year price hikes to no more than the rate of inflation.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.